CityBizList – Led by Peter Kolchinsky, Boston-based hedge fund manager RA Capital Management, LLC openly criticizes Cypress Bioscience, Inc. in a recent SEC filing.
The filing – which shows that RA Capital owns a 5.46 percent stake in, or 2,107,392 shares of the pharmaceutical company, worth $7.33 million as of Monday’s close – contains a letter in which Kolchinsky advises Cypress Bioscience to negotiate with Ramius, an alternative investment management business headquartered in New York, and any other party for an acquisition of Cypress at a price of $4.00 per share.
